Guardian Pharmacy Services, Inc. (NYSE:GRDN) Insider Sells 350,058 Shares

Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) insider Kendall Forbes sold 350,058 shares of the company's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $7,057,169.28. Following the completion of the sale, the insider now directly owns 268,897 shares of the company's stock, valued at $5,420,963.52. The trade was a 56.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kendall Forbes also recently made the following trade(s):

• On Wednesday, May 28th, Kendall Forbes sold 64,991 shares of Guardian Pharmacy Services stock. The stock was sold at an average price of $20.16, for a total value of $1,310,218.56.

Guardian Pharmacy Services Stock Up 2.3%

Guardian Pharmacy Services stock traded up $0.49 during midday trading on Tuesday, hitting $21.78. The stock had a trading volume of 290,686 shares, compared to its average volume of 169,453. The business has a fifty day moving average price of $23.18 and a 200 day moving average price of $22.01. Guardian Pharmacy Services, Inc. has a 12 month low of $14.16 and a 12 month high of $26.91.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.01). The company had revenue of $329.31 million during the quarter, compared to analyst estimates of $321.21 million. On average, sell-side analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Institutional Trading of Guardian Pharmacy Services

Hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in shares of Guardian Pharmacy Services in the 4th quarter worth about $30,000. BNP Paribas Financial Markets bought a new position in Guardian Pharmacy Services in the 4th quarter worth about $37,000. Compass Financial Services Inc bought a new position in Guardian Pharmacy Services in the 4th quarter worth about $58,000. JPMorgan Chase & Co. bought a new position in Guardian Pharmacy Services in the 4th quarter worth about $77,000. Finally, Quantbot Technologies LP bought a new position in Guardian Pharmacy Services in the 4th quarter worth about $81,000.

Analysts Set New Price Targets

Several brokerages have issued reports on GRDN. Raymond James set a $28.00 price objective on shares of Guardian Pharmacy Services and gave the company an "outperform" rating in a research report on Wednesday, May 14th. Wall Street Zen lowered Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Truist Financial reiterated a "buy" rating and set a $28.00 target price (up from $25.00) on shares of Guardian Pharmacy Services in a research note on Monday, May 19th.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.